Spots Global Cancer Trial Database for A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy

Official Title: Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels, of Patients With Anemia Reklated to Malignant Tumors, Treated With Erythropoietin B (Recormon) Using the Pre-Filled Syringe With 30,000 IU, as Well as to Quantify Teh Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment

Study ID: NCT02624141

Conditions

Anemia

Interventions

Epoetin Beta

Study Description

Brief Summary: This study will examine the efficacy, safety, and effect on hemoglobin levels, of once weekly epoetin beta subcutaneous injections (30,000 International Units \[IU\]) in anemic patients with solid tumors. The anticipated study duration is 4 months, and the target sample size is 40 individuals.

Detailed Description: